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ABSTRACT.
Purpose: To analyse intraocular cytokine levels and prevalence of intraocular
antiretinal antibodies (ARAs) in patients with retinitis pigmentosa (RP), age-
related macular degeneration (AMD), glaucoma and cataract, and correlate the
results to clinical manifestations.
Methods: We collected intraocular fluid samples from patients with RP
(n = 25), AMD (n = 12), glaucoma (n = 28) and cataract (n = 22), and serum
samples paired with the intraocular fluids from patients with RP (N = 7) and
cataract (n = 10). Interleukin (IL)-1b, IL-1ra, IL-2, IL-6, IL-6ra, IL-7, IL-8,
IL-10, IL-17A, IL-23, thymus- and activation-regulated chemokine (TARC),
monocyte chemoattractant protein-1 (MCP-1), tumour necrosis factor-alpha
(TNF-a), placental growth factor (PlGF) and vascular endothelial growth factor
(VEGF) were measured using a multiplex assay. Antiretinal antibodies (ARA)
detection was performed by indirect immunofluorescence.
Results: Increasing age was associated with increasing levels of IL-6, IL-8,
TNF-a and VEGF. All patient groups exhibited distinct profiles of intraocular
cytokines. Intraocular levels of IL-8 were highest in patients with AMD and
glaucoma. Cataract patients exhibited high intraocular levels of IL-23.
Intraocular levels of IL-2, IL-6, MCP-1 and PlGF in RP patients exceeded
the levels of serum, indicating intraocular production. Intraocular ARAs were
found in only one patient with AMD.
Conclusion: Increased levels of inflammatory cytokines in intraocular fluid of
patients with originally noninflammatory ocular diseases show that intraocular
inflammation is involved in their pathogenesis of these entities. Moreover, we
show that increasing age is associated with increasing levels of intraocular
cytokines and conclude that future studies on intraocular mediators should be
corrected for age of patients.
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Introduction
The pathogenesis of retinitis pigmen-
tosa (RP), age-related macular degen-
eration (AMD) and glaucoma is not
fully clariﬁed, but a growing body of
evidence documents the involvement of
the immune system. Further insights
into the role of immune activation
could lead to potential new therapeutic
modalities for these blinding diseases.
Recent studies identiﬁed autoanti-
bodies directed against retinal tissue in
serum of patients with RP, AMD and
glaucoma.(Bell et al. 2013; Nussenblatt
et al. 2013) An association between
antiretinal antibodies (ARAs) in
serum and macular oedema has been
observed in RP.(Heckenlively et al.
1999) Decrease in serum ARA levels
was reported after intravitreal antivas-
cular endothelial growth factor
(VEGF) therapy in AMD.(Kubicka-
Trzaska et al. 2016) Also, a variant of
the complement factor H (CFH) gene,
which causes uncontrolled comple-
ment activation, has been linked to
AMD.(Nussenblatt et al. 2013) The
presence of ARAs in aqueous humour
and serum has been observed in
patients with glaucoma and in neurode-
generative damage of the optic nerve.(-
Joachim et al. 2007) Further, the
elevated levels of diﬀerent chemokines,
including monocyte chemotactic pro-
tein 1 (MCP-1) and interleukin (IL)-8,
as well as the pro-inﬂammatory cyto-
kine IL-6, have been described in
aqueous humour of RP, AMD and
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glaucoma.( Chiu et al. 2010; Jonas
et al. 2012; Freedman & Iserovich
2013; Yoshida et al. 2013; Chalam
et al. 2014; Rezar-Dreindl et al. 2016).
Autoimmune reactions against
retina, choroid and/or retinal pigment
epithelium (RPE) might contribute to
continuation and/or aggravation of
some of these initially noninﬂamma-
tory ocular diseases.( Nussenblatt et al.
2013; Kauppinen et al. 2016; Feng
et al. 2017; Rezar-Dreindl et al. 2017;
Shiraya et al. 2017) However, the role
of autoimmune reactions within the eye
and comparison of inﬂammatory reac-
tions between diﬀerent degenerative
ocular diseases have been scarcely
addressed.
Herein, we investigate speciﬁc cyto-
kine, chemokine and growth factor
levels and the presence of ARAs in
intraocular ﬂuid samples in patients
with RP, AMD, glaucoma and cataract
and relate the laboratory outcomes to
clinical manifestations.
Patients and Methods
Sample collection
In this cross-sectional study, we
obtained intraocular ﬂuid samples
from 87 patients with RP, AMD,
glaucoma and cataract (controls) from
the biobank at the Erasmus University
Medical Center and the biobank of the
Rotterdam Eye Hospital. Ocular ﬂuids
within the biobank were collected dur-
ing the beginning of a cataract extrac-
tion. The study was approved by the
local ethics committee from the Eras-
mus University Medical Center
(Medical Ethics Committee Erasmus
MC) and the ethics committee from the
institutional research board from the
Rotterdam Eye Hospital and adhered
to the tenets of the Declaration of
Helsinki. All intraocular ﬂuid samples
were stored at 80 °C. Serum samples
paired with intraocular ﬂuids of seven
patients with RP and 10 patients with
age-related cataract were also obtained
from the biobank.
Patient and data collection
The diagnosis of RP was based on
clinical characteristics such as night
blindness, visual ﬁeld constriction,
retinal abnormalities observed through
fundoscopy and/or electroretino-
graphic changes conﬁrming the
presence of RP-related photoreceptor
damage. The diagnosis of AMD was
carried out through clinical examina-
tion and optical coherence tomogra-
phy. The diagnosis of glaucoma was
based on the clinical presentation with
high intraocular pressure, optic nerve
damage and/or on characteristic visual
ﬁeld loss. Participants suﬀering from
ocular comorbidity or from a combi-
nation of included ocular diseases were
excluded.
Clinical characteristics of all patients
were collected. For RP patients, the
presence of cystoid maculopathy (CM)
was assessed as follows: (1) no CM, (2)
any prior CM and/or (3) current CM
(<4 weeks prior to sample collection).
For patients with AMD, diﬀerentiation
between exudative and dry AMD was
made and treatment with anti-VEGF
was noted: (1) no anti-VEGF medica-
tion, (2) any prior use of anti-VEGF
medication and/or (3) current use of
anti-VEGF medication (<4 weeks prior
to sample collection). Patients with
glaucoma were classiﬁed by the type
of their glaucoma. Prescription of anti-
hypertensive eye drops and ﬁltrating
surgery prior to sample collection were
registered.
Cytokine analysis
Measurement of interleukins (IL-1 b,
IL-1ra, IL-2, IL-6, IL-6ra, IL-7, IL-
8, IL-10, IL-17A, IL-23), thymus-
and activation-regulated chemokine
(TARC), MCP-1, tumour necrosis fac-
tor-alpha (TNF-a), placental growth
factor (PlGF) and VEGF was per-
formed with a Luminex multiplex bead
immunoassay system (R&D Systems
Europe, Ltd; UK). The selection of the
cytokine panel was based on potential
relevance according to previous reports
and/or possible targets for treatment
options.( Yoshida et al. 2013; Chalam
et al. 2014; Huang et al. 2014; Du
et al. 2016; Rezar-Dreindl et al. 2016)
The assays were performed according
to the manufacturer’s instructions with
exception of one additional dilution
step within the standards (in total 7
standard dilutions). Fifty microlitres of
undiluted intraocular ﬂuid samples was
transferred to the plate, with the excep-
tion of intraocular ﬂuid samples
with insuﬃcient amount of material
(n = 16), which were diluted to a total
volume of 50 ll. Serum samples were
diluted twofold according to the
manufacturer’s standard protocol.
Measurements were performed on a
Bio-Plex MAGPIX machine, and data
were analysed using Bio-Plex Manager
MP software.
Antiretinal antibody analysis
The presence of ARAs was assessed by
indirect immunoﬂuorescence (IIF)
using primate retinal tissue (Euroim-
mun) and evaluated as described before
in ten Berge et al.(Ten Berge et al.
2016) IIF was conducted with intraoc-
ular ﬂuids samples with suﬃcient
volume available and on all serum
samples. Samples that displayed
nuclear staining on retinal tissue were
also analysed in a routine IIF antinu-
clear antibody (ANA) screening test
using HEp-2 cells (Inova), to exclude
nonspeciﬁc retinal staining due to
ANA positivity, as described previ-
ously. (Ten Berge et al. 2016).
Statistical analysis
Data from the Luminex immunoassay
were analysed both as continuous data
and as categorical data. For the contin-
uous analyses, values below the lower
limit of detection were replaced by the
lowest value of the reference curve. For
categorical analyses, we used the lowest
value of the reference curve as cut-oﬀ
point. Continuous variables were sum-
marized using medians and ranges, and
categorical variables were summarized
using percentages. Logistic regression
for categorical data and linear regres-
sions for continuous data were assessed
to compare laboratory outcomes
between diagnosis groups. Age, gender
and diagnosis were included in the
regression model, to correct for con-
founders and analyse the eﬀect of each
of these variables. Statistical analyses
were performed using IBM SPSS Statis-
tics, version 21, and a p-value of <0.05
was considered as statistically signiﬁ-
cant.
Results
Patient characteristics
Aqueous humour samples were
obtained from a total of 87 patients:
RP (n = 25), AMD (n = 12), glaucoma
(n = 28) and cataract (n = 22). Serum
samples obtained simultaneously with
intraocular ﬂuids samples were
2
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available from 17 patients: RP (n = 7)
and cataract patients (n = 10). Gender
distribution did not diﬀer between
groups, but age diﬀered signiﬁcantly
(p < 0.001); speciﬁcally, patients with
AMD were older and patients with RP
were younger (Table 1). The AMD
group consisted of 10 patients with
dry and two patients with exudative
AMD. The classiﬁcation of glaucoma
included primary open-angle glaucoma
(POAG, n = 22), narrow-angle glau-
coma (n = 4), normal tension glau-
coma (n = 1) and glaucoma secondary
to pigment dispersion syndrome
(n = 1).
Prevalence of intraocular cytokines
The prevalence of cytokines, chemoki-
nes and growth factors in intraocular
ﬂuid is summarized in the Table S1.
Gender did not inﬂuence the preva-
lence of cytokines. After correction for
diagnosis, the prevalence of intraocular
IL-6 and TNF-a increased with age
(p = 0.012 and p = 0.002, respectively).
Interleukin (IL)-2 and MCP-1 were
present in all intraocular ﬂuid samples,
while IL-1 b and IL-17A were unde-
tectable in all intraocular ﬂuid samples.
Thymus- and activation-regulated che-
mokine (TARC) was detected in
intraocular ﬂuid of patients with RP,
AMD and glaucoma, but not in
cataract patients. Diﬀerences in the
presence of cytokines in intraocular
ﬂuids between ocular diseases were,
however, not signiﬁcant. No associa-
tions were found between clinical char-
acteristics (such as duration of disease,
clinical manifestations, use of systemic
and topical medications, previous
intraocular surgeries and others) and
the mere presence of cytokines,
chemokines or growth factors in
intraocular ﬂuid.
Prevalence of cytokines in paired
intraocular and serum samples
A similar cytokine proﬁle was found in
serum and intraocular ﬂuid in RP
patients, except for IL-2 and IL-6,
which were more often present in the
intraocular ﬂuid samples, and IL-1ra
and TARC, which were more fre-
quently observed in serum. The pres-
ence of serum cytokines was not
diﬀerent between RP patients and
cataract patients.
Levels of intraocular cytokines
Linear regressions using speciﬁc diag-
nosis, age and gender in the model
showed that intraocular levels of IL-6,
TNF-a and VEGF correlated posi-
tively with age (p = 0.009, p = 0.019
and p < 0.001, respectively; borderline
association was observed also for IL 8;
p = 0.049, Fig. 1). Gender showed no
association with intraocular cytokine
levels. Diﬀerent cytokine proﬁles were
observed for RP, AMD, glaucoma and
cataract; speciﬁcally, intraocular levels
of IL-6ra (p = 0.019), IL-8 (p = 0.032),
and IL-23 (p < 0.004) diﬀered between
the studied ocular diseases (Fig. 2).
Retinitis pigmentosa (RP) patients
were characterized by low levels of
intraocular IL-8 and IL-23. Intraocular
IL-8 levels were highest in patients with
AMD and glaucoma. Cataract patients
had high levels of IL-23. Intraocular
levels of IL-6ra were higher in patients
with RP or glaucoma than in patients
with AMD or cataract. Vascular
endothelial growth factor (VEGF)
levels were highest in intraocular ﬂuids
of AMD patients and lowest in RP,
although the diﬀerences did not reach
signiﬁcance after correction for age
(Table 2).
Retinitis pigmentosa (RP patients
who ever had CM during their disease
course exhibited lower intraocular IL-2
levels than RP patients without CM
(p = 0.042). Glaucoma patients treated
with antihypertensive eye drops dis-
played lower intraocular IL-6 levels
compared to glaucoma without this
treatment modality (p < 0.001). Glau-
coma patients who previously under-
went surgical treatment (11/28, 39%;
consisting of selective laser therapy,
trabeculectomy or occasional glau-
coma implants) exhibited higher
intraocular IL-8 levels (p = 0.035). No
other associations were found between
clinical characteristics (such as dura-
tion of disease, use of systemic or
topical medications) and the levels of
cytokines, chemokines or growth fac-
tors in intraocular ﬂuid.
Levels of cytokines in paired intraocular
and serum samples
Interleukin (IL)-2, IL-6, MCP-1 and
PlGF levels were higher in intraocular
ﬂuid than in serum in both RP
(p < 0.001, p = 0.001, p < 0.001 and
p = 0.006) and cataract (p < 0.001,
p = 0.047, p < 0.001 and p < 0.001).
Moreover, cataract patients had higher
levels of IL-23 in intraocular ﬂuid than
serum (p = 0.043). In contrast, intraoc-
ular IL-23 levels in RP were lower than
the serum levels (p < 0.001). Intraocu-
lar levels of all other cytokines,
chemokines and growth factors in
intraocular ﬂuid did not exceed serum
levels. Levels of serum cytokines were
not diﬀerent between RP patients and
cataract patients.
Prevalence of antiretinal antibodies
Antiretinal antibodies (ARAs) were
not detected in intraocular ﬂuid sam-
ples from RP (n = 21), glaucoma
(n = 18) and cataract (n = 16). In one
patient with AMD (1/8, 13%), intraoc-
ular ARA were detected. Serum ARA
levels were detected in ﬁve of seven
(71%) patients with RP and six of 10
(60%) patients with cataract. All sam-
ples with nuclear staining on retinal
tissue (n = 7) were negative for ANA.
Discussion
Our study describes diﬀerent pro-
inﬂammatory intraocular cytokine pro-
ﬁles in RP, AMD, glaucoma and
cataract and reveals a positive correla-
tion between intraocular cytokine
levels and increasing age,
Table 1. Patient characteristics.
Retinitis pigmentosa Age-related macular degeneration Glaucoma Cataract p-value
Total number of patients N = 25 N = 12 N = 28 N = 22
Median age in years (range) 51 (25-86) 84 (68-94) 73 (50-88) 66 (17-80) < 0.001
Gender (male) 12/25 (48%) 3/12 (25%) 13/28 (46%) 8/22 (36%) n.s.
n.s. = not statistically signiﬁcant (p > 0.05).
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independently of diagnosis. Interest-
ingly, intraocular ﬂuid samples from
cataract patients displayed the highest
levels of IL-23. Although intraocular
levels of VEGF were highest in AMD
patients, after age correction, no sig-
niﬁcant diﬀerences were found between
the various diagnostic groups. Com-
parison of paired serum and intraocu-
lar ﬂuid samples of RP patients showed
that intraocular levels of IL-2, IL-6,
MCP-1 and PlGF exceeded the serum
levels, suggesting a local production.
Intraocular ARAs were absent in
nearly all samples.
Although a genetic mutation is the
cause of RP, inﬂammation was sug-
gested to have a (secondary) role in the
disease pathogenesis.(Chant et al. 1985;
Nussenblatt et al. 2013; Hettinga et al.
2016). It has been previously reported
that RP patients with CM exhibited
more often ARAs in their peripheral
blood, the ﬁnding which was also noted
in present series. (Heckenlively et al.
1999). In contrast to serum ﬁndings,
ARAs were not detected in intraocular
ﬂuids samples of patients with RP.
Previous reports on intraocular
cytokines in RP show higher levels of
IL-6, IL-8, MCP-1 and TARC in RP
compared to cataract.(Salom et al.
2008; Yoshida et al. 2013) We also
observed intraocular presence of these
mediators in RP patients, but their
levels were not elevated compared to
other groups. This discrepancy may be
explained by the low number of
included patients in our study or pos-
sible diﬀerences in disease stage and/or
extent of degeneration. Yet RP
patients, like glaucoma patients, had
higher intraocular levels of soluble IL-
6ra (sIL-6Ra) compared to cataract.
Soluble IL-6ra (sIL-6Ra) interacts with
IL-6, forming the IL-6/sIL-6Ra com-
plex, which subsequently induces IL-6
trans-signalling by binding cell mem-
brane expressed gp130.(Rose-John
2012) IL-6 trans-signalling is recog-
nized to enhance IL-6 activity under
inﬂammatory conditions and moreover
to inhibit intraocular T-cell apoptosis
in uveitis, which likely exacerbates or
prolongs the disease process. (Nowell
et al. 2003; Curnow et al. 2004;
Barkhausen et al. 2011) Further, we
observed a signiﬁcant association
between lower levels of intraocular
IL-2 (a growth factor for regulatory T
cells) in RP patients who had CM. This
may indicate a deregulated immune
function, such as loss of tolerance,
aﬀecting the clinical manifestation of
the disease and the formation of serum
ARAs as observed in this and other
studies.(Nelson 2004) Intraocular
VEGF levels were lowest in the RP
group, which is in line with the rare
presence of retinal neovascularization
in RP.
Inﬂammation was implicated in the
development and progression of
AMD.(Adamus 2017) So far, most
previous studies investigated intraocu-
lar ﬂuids of exudative AMD, demon-
strating high levels of inﬂammatory
mediators, including IL-6, IL-8,
MCP-1 and VEGF.(Jonas et al. 2012;
Knickelbein et al. 2015) However, it is
still unknown whether these cytokines
play a role in the primary pathogenesis
of AMD or represent a secondary
result of the disease process. We
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Fig. 1. Levels of intraocular cytokines in relation to age. p-values for comparison of intraocular cytokine levels and age were determined by linear
regression with adjustment for diagnosis and gender.
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investigated patients with mainly dry
AMD and observed higher intraocular
IL-8 compared to cataract and RP.
Previous studies revealed that elevated
(intraocular) levels of IL-8 and IL-8
gene polymorphisms were associated
with angiogenesis.( Ghasemi et al.
2011; Forooghian et al. 2016) IL-6
and VEGF reached highest levels in
the AMD group, though not signiﬁ-
cantly diﬀerent compared to other
diagnosis groups. According to previ-
ous studies, these mediators have been
implicated in angiogenesis and decrease
during treatment with anti-VEGF
agents. (Agawa et al. 2014; Chalam
et al. 2014) Retinal neuroprotective
eﬀects of VEGF have also been
described, yet data on this matter are
inconclusive and may be dependent on
the VEGF variant, disease (stage) or
experimental model used.(Nishijima
et al. 2007; Saint-Geniez et al. 2008).
In glaucoma, the role of immune
reactions is not known and could be
either pathogenic or neuroprotective.
In our study, patients with glaucoma,
who consisted mainly of POAG, were
characterized by high intraocular levels
of IL-8, consistent with previous ﬁnd-
ings.( Kuchtey et al. 2010; Takai et al.
2012; Khalef et al. 2017; Kokubun
et al. 2017) IL-8 is a main chemoat-
tractant for neutrophils which have
been found to accumulate in the tra-
becular meshwork in POAG.(Taurone
et al. 2015) The highest levels of IL-8
were found in glaucoma patients who
underwent surgical treatment prior to
the surgical procedure during intraoc-
ular sample collection. This suggests
that the higher levels of IL-8 might be
explained by immune activation in
response to (surgically inﬂicted) tissue
damage.
Increased TNF-a levels have been
reported in intraocular ﬂuid, the tra-
becular meshwork, optic head and the
retina of glaucoma patients; however,
in our study, intraocular TNF-a
appeared undetectable in most cases.
(Yuan & Neufeld 2000; Tezel et al.
2001; Sawada et al. 2010; Balaiya
et al. 2011; Taurone et al. 2015; Khalef
et al. 2017) This discrepancy may have
resulted from diﬀerences in laboratory
techniques and speciﬁc patient groups.
So far, to our knowledge, only sporadic
studies are available on the eﬀect of
anti-TNF medication in glaucoma,
which shows an increase in ﬁbrosis
after surgical treatment.(Nikita et al.
2017).
In our study, cataract was generally
characterized by lower levels of pro-
inﬂammatory mediators compared to
other studied diseases, with the excep-
tion of IL-23. IL-23, produced by
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Fig. 2. Levels of intraocular cytokines in relation to ocular diagnosis. p-values for comparisons of
intraocular cytokine levels within retinitis pigmentosa, age-related macular degeneration,
glaucoma and cataract were determined by linear regression with adjustment for age and gender.
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dendritic cells/myeloid cells, is well
known for its key role in several
autoimmune diseases via the IL-23/
IL-17 axis and associated pathological
Th17 development.(D’Elios et al. 2010;
Lubberts 2015) Despite the presence of
IL-23 in most intraocular ﬂuids anal-
ysed in our study, IL-17A was never
detected. Interestingly, some studies
report immunosuppressive eﬀects of
IL-23 within tumour microenviron-
ments by suppressing lymphocyte eﬀec-
tor function and enhanced production
of immune regulatory cytokines.(Lan-
gowski et al. 2006; Teng et al. 2010;
Nie et al. 2017) Also in a model of
experimental autoimmune uveitis, it
was found that IL-23 receptor express-
ing cd T cells can exert immune-
suppressive eﬀects due to their ability
to bind IL-23.(Liang et al. 2013)
Although the mechanism by which
IL-23 can mediate immune-suppressive
eﬀects clearly requires further study, it
is tempting to speculate that the low
intraocular IL-23 levels observed in
patients with RP, AMD and glaucoma
may reﬂect diminished immune protec-
tion of the eye. Intraocular IL-23 levels
revealed no association with serum
levels nor with age of patients.
Ageing is associated with the devel-
opment of a chronic state of low-grade
tissue inﬂammation that also involves
the retina and is associated with
increased susceptibility to multiple dis-
eases, including glaucoma and AMD.(
Leske et al. 2008; Xu et al. 2009;
Chakravarthy et al. 2010; Castelo-
Branco & Soveral 2014) In support of
this, we observed a gradual increase in
the intraocular levels of IL-6, IL-8,
TNF-a and VEGF with increasing age.
A positive correlation between intraoc-
ular cytokine levels and age has been
reported in two previous studies.( Takai
et al. 2012; Kokubun et al. 2017) As a
consequence of this correlation, all of
our results are adjusted for the age of
patients. However, systematic correc-
tions for age have not been performed
in previous studies, which may have
aﬀected the interpretation of these ﬁnd-
ings. It should thus be kept in mind that
studies on intraocular cytokine proﬁling
without age adjustment (and without
age matched control groups) may show
age-related bias rather than disease-
associated diﬀerences.
Intraocular levels of IL-2, IL-6,
MCP-1 and PlGF were higher than
the serum levels of patients with RPT
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and cataract. The higher intraocular
levels of inﬂammatory components
may suggest local production, possibly
by inﬁltrated immune cells or resident
cells, such as retinal pigment epithelial
cells.(Elner et al. 1992; Holtkamp et al.
1998) These ﬁndings may contribute to
the understanding of the pathogenesis of
RP and development of new treatment
possibilities. In contrast, the low occur-
rence of intraocular ARAs suggests a
negligible role of such antibodies in
disease pathogenesis of RP. Antiretinal
antibodies (ARAs) detected in serum
from RP and cataract patients may
represent a reﬂection of altered blood
retinal barrier properties and most
probably represent an innocent epiphe-
nomena.
In this study, we investigated a
variety of patients with diﬀerent ocular
disorders that are classically considered
as being noninﬂammatory. Even with
the limited number of divers patients,
we were able to conclude that autoim-
mune reactions are prevalent in origi-
nally noninﬂammatory ocular diseases.
To our knowledge, our study is the
only study so far assessing and com-
paring the role of inﬂammatory
responses in diﬀerent noninﬂammatory
ocular diseases. The replacement of
values of cytokine levels below the
lowest standard by the lowest detection
limit by the lowest value of the refer-
ence curve might have inﬂuenced our
outcomes. However, omitting data
below the lower limit of detection
might cause selection bias.
In conclusion, the expression of
inﬂammatory cytokines within the eye
was strongly inﬂuenced by the age of
patients, which shows that the correc-
tion for age is necessary in future
studies on intraocular mediators. Dif-
ferences in intraocular cytokine proﬁles
were observed between originally non-
inﬂammatory ocular diseases, suggest-
ing involvement of inﬂammation;
however, complex pathways with mul-
tiple signalling functions make a diag-
nostic role rather impossible. The role
of immune reactions in basically non-
inﬂammatory ocular diseases might
inﬂuence the clinical manifestations
and severity of ocular changes.
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